Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 30, 2018 08:58 ET | Source: Sedor Pharmaceuticals

Sedor Pharmaceuticals NDA for CE-Fosphenytoin for Status Epilepticus Receives PDUFA Date

PAOLI, Pa., July 30, 2018 (GLOBE NEWSWIRE) -- Sedor Pharmaceuticals, LLC (Sedor) announced that the US FDA accepted its 505(b)2 NDA (210864) for Sedor’s lead program, IM/IV Captisol-Enabled™ (CE)...
May 30, 2018 13:57 ET | Source: Sedor Pharmaceuticals

Sedor Pharmaceuticals and Los Altos Pharmaceuticals sign license agreement for People’s Republic of China

PAOLI, Pa. and LOS ALTOS HILLS, Calif., May 30, 2018 (GLOBE NEWSWIRE) -- Sedor Pharmaceuticals, LLC (Sedor) and Los Altos Pharmaceuticals, Inc. (Los Altos) announce that Sedor has granted Los Altos...
May 30, 2018 13:46 ET | Source: SEDOR Pharmaceuticals

Sedor Pharmaceuticals Receives Major Milestone Payment

PAOLI, Pa. and SHANXI, China, May 30, 2018 (GLOBE NEWSWIRE) -- Sedor Pharmaceuticals, LLC (Sedor) and Xi’an Xintong Pharmaceutical Research Co., Ltd (Xintong) announce that Xintong has provided...
May 30, 2018 11:07 ET | Source: SEDOR Pharmaceuticals

Sedor Pharmaceuticals Files NDA for CE-Fosphenytoin for Status Epilepticus

PAOLI, Pa., May 30, 2018 (GLOBE NEWSWIRE) -- Sedor Pharmaceuticals, LLC (Sedor) announced that it has filed with the US FDA an NDA for the approval of Sedor’s lead program, IM/IV Captisol-Enabled™...